<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365883">
  <stage>Registered</stage>
  <submitdate>28/02/2014</submitdate>
  <approvaldate>6/03/2014</approvaldate>
  <actrnumber>ACTRN12614000239662</actrnumber>
  <trial_identification>
    <studytitle>Treatment of type 2 diabetes with antioxidant vitamin C therapy</studytitle>
    <scientifictitle>Placebo-controlled cross-over trial investigating high dose oral vitamin C supplementation in people with type 2 diabetes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes </healthcondition>
    <healthcondition>skeletal muscle insulin resistance</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will orally consume either 2 x 500mg ascorbic acid or 2 x placebo capsules daily for four months.  A 4-week wash-out period will separate treatments.  Trial order will be randomized.</interventions>
    <comparator>identical-looking placebo capsules containing gelatin</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Measurement of insulin sensitivity using a euglycaemic, hyperinsulinaemic clamp coupled with the infusion of a stable glucose tracer (assessed using gas chromatography/mass spectrometry (GC/MS) methods)</outcome>
      <timepoint>Immediately before and immediately after both 4-month interventions.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Measurement of vitamin C status in skeletal muscle and plasma, measured using high performance liquid chromatography (HPLC).</outcome>
      <timepoint>Immediately before and immediately after both 4-month interventions.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Males and females with type 2 diabetes, no major medical illness apart from T2D, aged 35-70 years</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>HbA1c &gt;6.5% and &lt;10.0%; total cholesterol &lt;6.5mmol.L-1; triglycerides &lt;4.0mmol.L-1; body mass index &lt;35kg.m-2; systolic blood pressure &lt;160mmHg; diastolic blood pressure &lt;90mmHg; smoking, a history of cardiovascular, renal, respiratory or neurological disease; a heart murmur condition or bleeding disorder; haemochromatosis or iron overload disorders; insulin therapy, on oral anti-hyperglycaemic medications other than metformin (no greater than 2000mg total per day) or sulfonylureas and/or a dipeptidyl-peptidase-4 inhibitors; taking vitamin or herbal supplements during month prior to participation; taking medications known to influence insulin sensitivity; and if pregnant or planning a pregnancy during the trial period.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants will undergo a screening session with our medical doctor during which a blood test and medical examination will occur to establish eligibility.
	Participant trial order will be determined by a third party individual not directly involved in the trial. This individual will conceal treatments and determined the randomized allocation of treatments.  Both vitamin C and placebo will be identical in appearance and sealed in identical opaque containers.
</concealment>
    <sequence>Randomized via coin toss</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>2/05/2011</anticipatedstartdate>
    <actualstartdate>1/03/2012</actualstartdate>
    <anticipatedenddate>1/06/2012</anticipatedenddate>
    <actualenddate>1/02/2013</actualenddate>
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Deakin University</primarysponsorname>
    <primarysponsoraddress>221 Burwood Hwy, Burwood Victoria 3125</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Deakin University</fundingname>
      <fundingaddress>221 Burwood Hwy, Burwood Victoria 3125</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Reactive oxygen species are the by-products of energy generation and thought to cause
problems with maintaining glucose levels in people with type 2 diabetes. Vitamin C (ascorbic
acid) is an antioxidant and is the most common vitamin supplement taken by adult Australians
(17% of the population). Its antioxidant effects might lower the levels of these reactive oxygen
species and improve the health of people with type 2 diabetes.
Aims:
To examine if antioxidant vitamin C supplementation reduces the levels of reactive oxygen
species and improves insulin sensitivity in skeletal muscle of people with type 2 diabetes.
Significance:
Studies that have examined the effectiveness of vitamin C supplementation in the treatment of
type 2 diabetes and insulin resistance in humans have so far produced conflicting and
disappointing results, due, at least in part, to inadequate study design and a failure to measure
the antioxidant action of vitamin C and insulin sensitivity at the key site of insulin action, which
is skeletal muscle.
The outcomes will likely contribute to new Australian health guidelines regarding the use of
antioxidant vitamin supplements for the treatment of insulin resistance in people with type 2
diabetes.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Deakin University Human Research Ethics Committee</ethicname>
      <ethicaddress>221 Burwood Hwy, Burwood Victoria 3125</ethicaddress>
      <ethicapprovaldate>14/12/2010</ethicapprovaldate>
      <hrec>2010-256</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Glenn Wadley</name>
      <address>Deakin University, School of Exercise and Nutrition Sciences,
221 Burwood Hwy, Burwood, Vic, 3125</address>
      <phone>+61 3 92446018</phone>
      <fax />
      <email>glenn.wadley@deakin.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Glenn Wadley</name>
      <address>Deakin University, School of Exercise and Nutrition Sciences,
221 Burwood Hwy, Burwood, Vic, 3125</address>
      <phone>+61 3 92446018</phone>
      <fax />
      <email>glenn.wadley@deakin.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Shaun Mason</name>
      <address>Deakin University, School of Exercise and Nutrition Sciences,
221 Burwood Hwy, Burwood, Vic, 3125</address>
      <phone>+61 392468285</phone>
      <fax />
      <email>smaso@deakin.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Shaun Mason</name>
      <address>Deakin University, School of Exercise and Nutrition Sciences,
221 Burwood Hwy, Burwood, Vic, 3125</address>
      <phone>+61 392468285</phone>
      <fax />
      <email>smaso@deakin.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>